tiprankstipranks
Advertisement
Advertisement

STOK Stock Latest News

Stoke Therapeutics, Biogen present long-term data on Zorevunersen
The FlyStoke Therapeutics, Biogen present long-term data on Zorevunersen
3d ago
BIIB
STOK
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
PremiumThe Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
6d ago
BIIB
STOK
Stoke Therapeutics reinstated with an Overweight at JPMorgan
PremiumThe Fly
Stoke Therapeutics reinstated with an Overweight at JPMorgan
17d ago
STOK
Stoke Therapeutics Charts Path From EMPEROR To Launch
PremiumCompany Announcements
Stoke Therapeutics Charts Path From EMPEROR To Launch
1M ago
STOK
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
PremiumRatings
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
1M ago
STOK
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
PremiumRatingsStoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
1M ago
STOK
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
Premium
Ratings
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
1M ago
STOK
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
Premium
Ratings
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
1M ago
STOK
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
PremiumRatings
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
1M ago
STOK
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
PremiumThe Fly
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
1M ago
STOK
Stoke Therapeutics Expands ATM Equity Program for Funding
PremiumCompany Announcements
Stoke Therapeutics Expands ATM Equity Program for Funding
1M ago
8K
STOK
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
PremiumThe Fly
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
1M ago
STOK
Stoke Therapeutics (STOK) Q2 Earnings Cheat Sheet
PremiumPre-EarningsStoke Therapeutics (STOK) Q2 Earnings Cheat Sheet
1M ago
STOK
Stoke Therapeutics appoints McCauley as Chief Scientific Officer
Premium
The Fly
Stoke Therapeutics appoints McCauley as Chief Scientific Officer
2M ago
STOK
Stoke Therapeutics initiated with a Buy at Goldman Sachs
Premium
The Fly
Stoke Therapeutics initiated with a Buy at Goldman Sachs
2M ago
STOK
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
PremiumCompany Announcements
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
2M ago
8K
STOK
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study
PremiumThe Fly
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study
2M ago
STOK
Stoke Therapeutics Stockholders Approve Directors and Governance Items
PremiumCompany Announcements
Stoke Therapeutics Stockholders Approve Directors and Governance Items
3M ago
8K
STOK
Stoke Therapeutics: Buy Rating Reiterated as Phase 3 Dravet Program Advances; $60 Price Target Maintained
PremiumRatings
Stoke Therapeutics: Buy Rating Reiterated as Phase 3 Dravet Program Advances; $60 Price Target Maintained
4M ago
STOK
Analyst Reiterates Buy on Stoke Therapeutics, Maintains $40 Price Target on Robust Dravet Data and Phase 3 Progress
PremiumRatingsAnalyst Reiterates Buy on Stoke Therapeutics, Maintains $40 Price Target on Robust Dravet Data and Phase 3 Progress
4M ago
STOK
Werber Reiterates Buy on Strong EMPEROR Phase 3 Progress, Durable Zorevunersen Data and Solid Cash Runway Through 2028
Premium
Ratings
Werber Reiterates Buy on Strong EMPEROR Phase 3 Progress, Durable Zorevunersen Data and Solid Cash Runway Through 2028
4M ago
STOK
Stoke Therapeutics reports Q1 EPS (79c), consensus (84c)
Premium
The Fly
Stoke Therapeutics reports Q1 EPS (79c), consensus (84c)
4M ago
STOK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >